Boris Bozic

Dr. Boris Bozic


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 October 2021 in Cancers
Verified
Journal Article
Open access
PDF file
BBBoris Bozic
Boris Bozic
JRJens Rutner
Jens Rutner
CZChang Zheng
Chang Zheng
RRReinhard Ruckser
Reinhard Ruckser
FSFlonza Selimi
Flonza Selimi
Christian SebestaChristian Sebesta
Christian Sebesta
Background: Renal insufficiency is one of the most frequent complications in multiple myeloma. The incidence of renal insufficiency in patients with multiple myeloma ranges from 20% to 50%. Renal impairment in patients with multiple myeloma results primarily from the toxic effects of monoclonal light chains on the kidneys. Dehydration, hypercalcemia, hyperuricemia, the application of nephrotoxic NSARs, antibiotics, contrast agents, etc., all play a major role in the deterioration of renal function in patients with multiple myeloma. The diagnosis and treatment of these patients use an interdisciplinary approach in consultation with hematologist–oncologists, radiologists, nephrologists and intensive care specialists. Using new drugs in the treatment of patients with refractory/relapsed multiple myeloma and renal insufficiency markedly improves progression-free survival and overall survival in these patients. Conclusions: New drugs have helped to widen the treatment options available for patients with renal impairment and refractory/relapsed multiple myeloma, since dose adjustments are unnecessary with carfilzomib as well as with panobinostat, elotuzumab, pomalidomide or daratumumab in patients with renal impairment. Several new substances for the treatment of refractory/relapsed multiple myeloma have been approved in the meantime, including belantamab mafodotin, selinexor, melflufen, venetoclax, CAR T-cell therapy and checkpoint inhibitors. Ongoing studies are investigating their administration in patients with renal impairment.

26 September 2022 in Wiener Medizinische Wochenschrift
Verified
Journal Article
Closed access
PDF file
DJDavid Jaros
David Jaros
BBBoris Bozic
Boris Bozic
Christian SebestaChristian Sebesta
Christian Sebesta